News Releases

Press Releases

Search Press Releases
  
Subscribe for Email Alerts
12/13/2018
2:00 PM ET
Press Release

Diffusion Pharmaceuticals Announces 1-for-15 Reverse Stock Split As Part Of NASDAQ Compliance Plan

12/13/2018

CHARLOTTESVILLE, Va., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical con...

 Continue Reading
11/15/2018
9:15 AM ET
Press Release

Diffusion Pharmaceuticals Chief Scientific Officer Dr. John L. Gainer to Present at 2018 Annual Meeting of the Society for NeuroOncology

11/15/2018

Poster Presentation to Focus on Phase 3 GBM Brain Cancer Clinical Trial; 40 Percent Survival Rate for Biopsy-only Patients in Phase 2 Represents Fourfold Increase Above Historical Average For Those Fa...

 Continue Reading
11/14/2018
9:00 AM ET
Press Release

Diffusion Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

11/14/2018

Highlights Include FDA Approval of Phase 2 On-Ambulance Clinical Trial for Treatment of Stroke and Appointment of New Chief Financial Officer

CHARLOTTESVILLE, Va., Nov. 14, 2018 (GLOBE NE...

 Continue Reading
10/15/2018
12:00 PM ET
Press Release

Diffusion Pharmaceuticals Chief Financial Officer William “Bill” Hornung to Present at 2018 BIO Investor Forum

10/15/2018

Over 1,000 Attendees Expected; Opportunity to Learn About Company’s FDA Approval for Phase 2 On-Ambulance Stroke Trial and Phase 3 GMB Brain Cancer Trial Enrollment

CHARLOTTESVILLE, Va., Oc...

 Continue Reading
9/25/2018
9:00 AM ET
Press Release

Diffusion Names William (“Bill”) Hornung Chief Financial Officer

9/25/2018

CHARLOTTESVILLE, Va., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical co...

 Continue Reading
9/12/2018
9:00 AM ET
Press Release

FDA Approves Start of Innovative On-Ambulance Phase 2 Clinical Trial for Treatment of Acute Stroke by Diffusion Pharmaceuticals

9/12/2018

CHARLOTTESVILLE, Va., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical co...

 Continue Reading
8/29/2018
8:00 AM ET
Press Release

Diffusion Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

8/29/2018

CHARLOTTESVILLE, Va., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on improving pati...

 Continue Reading
Displaying 1 to 7 (of 105 releases)